Neuromyelitis Optica Spectrum Disorder (NMOSD) – Executive Insights – Executive Insights (US/EU5)
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, chronic neuroinflammatory disorder that can lead to blindness and paralysis. Most patients have a relapsing form of the disease, leading to progressively worsening disability. Three therapies have been approved in the markets under study to treat NMOSD: Alexion Pharmaceuticals’ Soliris (eculizumab), Roche / Chugai / Genentech’s Enspryng (satralizumab), and Horizon Therapeutics’ Uplinza (inebilizumab). However, their use is constrained by safety concerns and high cost. Thus, off-label therapies such as rituximab, corticosteroids, or immunosuppressive therapy are often used, particularly in early lines of treatment, for both acute and long-term management of NMOSD. While the need for additional therapies is critical, improvements in diagnostics and disease understanding are also essential to facilitate advances in the treatment and management of NMOSD.
QUESTIONS ANSWERED
- What is the diagnosed prevalence of NMOSD in the United States and Europe, and how is the diagnosis made?
- How do approved NMOSD therapies (Soliris, Uplinza, and Enspryng) fit into the treatment algorithm for NMOSD? What are the advantages and disadvantages of these drugs?
- What are the key areas of unmet need and opportunity in the management of NMOSD?
- What is the state of the pipeline of NMOSD drugs, and what influence will emerging therapies have on the future NMOSD market?
PRODUCT DESCRIPTION
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
Geography: United States, EU4, United Kingdom
Primary Research: 12 KOL interviews in October 2021
Key Companies Covered: Alexion Pharmaceuticals, Horizon Therapeutics, Roche / Chugai / Genentech
Key Drugs Covered: Enspryng, Soliris, rituximab (Rituxan, biosimilars), Ultomiris, Uplizna, 9 preclinical and Phase I assets.
Table of contents
- Neuromyelitis Optica Spectrum Disorder (NMOSD) - Executive Insights - Executive Insights (US/EU5)
- Neuromyelitis Optica Spectrum Disorder | Executive Insights | US/EU5 | 2021
Shilpa Verma, B.Pharm., Manager, Healthcare Research & Data Analytics, Infectious, Niche, and Rare Diseases. She has more than 11 years of work experience in competitive intelligence and medical affairs. Her expertise is in infectious diseases and immuno-inflammatory diseases. She received her bachelor’s degree in pharmacy from the Indian Institute of Technology at Banaras Hindu University. She also has a postgraduate degree in business management from the Narsee Monjee Institute of Management Studies.
Prior to joining Clarivate, Ms. Verma worked for WNS and Evalueserve, where her clients included leading pharmaceutical companies. She is also an expert in HIV. She did her internship at AstraZeneca and has experience working in the quality control department.
Bethany A. Kiernan, Ph.D., Director, Healthcare Research & Data Analytics, Infectious, Niche, and Rare Diseases. Dr. Kiernan manages and supports a team of analysts and managers producing both syndicated and custom market research analyses in a range of niche / rare indications as well as infectious diseases. Dr. Kiernan has extensive experience in market forecasting and broad knowledge across a range of CNS disorders, rare diseases, and infectious diseases. Her previous experience includes eight years of scientific research conducted at Tufts University School of Medicine, Case Western Reserve University, and the College of the Holy Cross. She earned her doctorate in neurosciences from Case Western Reserve University.